MARKET

CYBN

CYBN

Cybin Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

0.7900
+0.0750
+10.49%
Closed 19:56 08/09 EDT
OPEN
0.8295
PREV CLOSE
0.7150
HIGH
0.8470
LOW
0.7400
VOLUME
1.00M
TURNOVER
--
52 WEEK HIGH
2.890
52 WEEK LOW
0.3903
MARKET CAP
131.23M
P/E (TTM)
-2.4428
1D
5D
1M
3M
1Y
5Y
This Psychedelics Company Is Setting Up An Equity Program For Up To $35M In Shares
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) has launched an at-the-market (ATM) equity program through which it will issue and sell up to $35 million in common shares in the company’s capital, from the treasury to the public.
Benzinga · 13h ago
Cybin, Field Trip Health Among Top Psychedelic Movers Of Today
 
Benzinga · 14h ago
Cybin stock jumps on announcing at-the-market equity program for up to $35M
Cybin (NYSE:CYBN) said Monday that it has <a href="https://seekingalpha.com/p...
Seekingalpha · 1d ago
Cybin reports FQ1 results
Cybin press release (N...
Seekingalpha · 1d ago
Cybin Announces Up To $35M At-The-Market Equity Program
Cybin Inc. (NEO: CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", announced today that it has
Benzinga · 1d ago
Cybin Announces Up to USD$35 Million At-The-Market Equity Program
TORONTO, August 08, 2022--Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", announced today that it has established an at-the-market equity program ...
Business Wire · 1d ago
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
TORONTO, August 08, 2022--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today reported unaudited financial results for its first quarter ended Jun...
Business Wire · 1d ago
GH Research, Numinus Wellness Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 29.83% at $15.80
Benzinga · 4d ago
More
No Data
Learn about the latest financial forecast of CYBN. Analyze the recent business situations of Cybin Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
57.14%Buy
0.00%Hold
0.00%Under-perform
14.29%Sell
Analyst Price Target
The average CYBN stock price target is 7.43 with a high estimate of 9.96 and a low estimate of 3.983.
High9.96
Average7.43
Low3.983
Current 0.7900
EPS
Actual
Estimate
-0.07-0.05-0.04-0.02
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.83%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Chairman/President/Executive Director
Eric So
Chief Executive Officer
Doug Drysdale
Co-Founder/Senior Vice President
John Kanakis
Chief Financial Officer
Greg Cavers
Chief Operating Officer
Aaron Bartlone
Chief Scientific Officer
Alex Nivorozhkin
Other
Alexander Belser
Other
Gabriel Fahel
Other
Brett Greene
Other
Michael Palfreyman
Director
Paul Glavine
Independent Director
Grant Froese
Independent Director
Eric Hoskins
Independent Director
Mark Lawson
No Data
No Data
About CYBN
Cybin Inc. is a Canada-based biopharmaceutical company, working with a network of partners and scientists to create therapeutics for patients to address a multitude of mental health issues. The Company operates in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. The Company’s products in pipeline include EMBARK, Kernel Flow, CYB003 (Deuterated Psilocybin Analog), CYB004 (Deuterated Dimethyltryptamine), and CYB005 (Phenethylamine Derivative). EMBARK is a Psilocybin for mental distress in frontline healthcare workers. The Company focuses on the clinical development of CYB004 for anxiety disorders, through its Phase I N,N-dimethyltryptamine (DMT) study. Its subsidiaries include Cybin Corp., Natures Journey Inc., Serenity Life Sciences Inc. and Cybin IRL Limited.

Webull offers kinds of Cybin Inc stock information, including AMEX:CYBN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYBN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYBN stock methods without spending real money on the virtual paper trading platform.